

Special Issue

Advancements in Bladder Cancer Therapy

Message from the Guest Editor

The field of bladder cancer has attracted significant attention in recent years with the introduction of new systemic therapy not only for metastatic disease but also for localized and non-muscle invasive disease. Moreover, molecular medicine and genetics are making impressive progress in the diagnostic and prognostic field. With both new treatment modalities and new diagnostic individualized work-up, we must rethink the whole field of bladder cancer surgery and treatment regimens. This Special Issue of *Cancers* will focus on both potential upcoming changes in regimens based on new diagnostics but also on new treatment strategies with a multimodal and individualized approach together with new emerging therapies in an otherwise well-known disease.

Guest Editor

Prof. Dr. Jørgen Jensen

1. Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
2. Department of Surgery, Queen Ingrid's Hospital, Greenland Centre for Health Research, Institute for Health and Nature Iisimatusarfik/University of Greenland, Nuuk, Greenland

Deadline for manuscript submissions

closed (31 May 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/210775

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)